Skip to main content

Raise Your Profile

Whether you are looking to attract a new business client, investment and partnering deal flow or talent, among other goals, One Nucleus offers a wide range of opportunities to raise your profile to our members and to the Greater Cambridge cluster in particular.
Raise Your Profile
  • Discounts for Members

    Discounts for Members

    Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. Receive discounted rates on laboratory supplies, services, key industry events and more.
    Learn more
  • Connect with Our Network

    Connect with Our Network

    A key advantage to any company joining One Nucleus is the ability to connect to potential partners, investors, service providers, clients and their peers for knowledge-sharing. We do this through our varied range of informative networking events, which tend to be situated throughout Cambridge and London.
    Learn more
  • Build the Best Teams

    Build the Best Teams

    One Nucleus recognises that a company’s employees are its most valuable asset and the competition for talented and skilled employees has never been fiercer in the region’s life science sector. One Nucleus offers a range of services and engagement opportunities in this critical area to help support our members and maintain the reputation of the sector.
    Learn more

Events

Connecting and meeting with business partners, fellow innovators and key advisers is a vital part of everyone's endeavours since it enables knowledge exchange and onward contact for mutual and collective success. Complementing the wider One Nucleus support activities our portfolio of events is designed to meet the needs of our network in terms of content, format, timing, peer-to-peer engagements and modes of delivery.
  • Events
  • Events
  • Events
  • Events

Membership Overview

With Gold and Silver membership options, our 400 company members and their staff can benefit from a wide variety of savings, profiling opportunities, and more.
  • Membership

About One Nucleus

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. 
  • About

Senior Commercialisation Manager (Biopharma)

The Senior Commercialisation Manager is an important position in the Biopharma team of QMI, playing a significant role in initiating and maintaining an effective commercialisation strategy for opportunities principally from the Barts and London School of Medicine and Dentistry.

The post-holder will contribute to the delivery of a range of outputs including technology disclosures, protection of university IP, license and investment transactions, and new venture formation.

How to build visibility on LinkedIn and use the platform more effectively

With almost 40m UK users, you can’t afford to ignore the power of LinkedIn to reach, connect and engage with other business users.

Join Dan Ince from social media agency BrandWorks Social for a thought-provoking talk on why you need to stand out more than ever on LinkedIn, and practical steps you can take to build visibility without it becoming overwhelming.

Discovery Park’s Chairman Dr. Martino Picardo Retires

Discovery Park is announcing the retirement of Dr. Martino Picardo, esteemed Chairman.

During his seven-year tenure at Discovery Park, Martino’s leadership drove transformative growth, with the Kent science and tech hub recognised as a Life Sciences Opportunity Zone and home to over 180 companies. Over a career spanning more than 30 years, Martino has continually championed the potential of the life sciences sector and the importance of building an environment for innovation to flourish.

Microbiotica reveals novel mechanisms showing how the microbiome can improve immunotherapy response based on MB097, a clinical-stage drug candidate being evaluated in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma

Data presented at AACR Annual Meeting in Chicago

Cambridge, UK – 29 April 2025: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), has presented new data on the mechanism of action of MB097 at the American Association for Cancer Research (AACR) annual meeting held in Chicago, April 25-30. MB097 is an LBP in development as a co-therapy for immune checkpoint inhibitors (CPI) such as MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).

Business Development Manager London (60-100% FTE)

One Nucleus is a dynamic not-for-profit Life Sciences and Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector. This support helps them achieve, or better still exceed, the goals they have set for themselves. Biomedical and Healthcare R&D has always been impactful in driving social and economic progress.

Metrion Biosciences launches NaV1.9 high-throughput screening assay to strengthen screening portfolio and advance research on new medicines for pain

  • Validated drug discovery assay overcomes previous challenges in targeting NaV1.9 ion channels for chronic pain signalling
  • Completes unique suite of rapid, scalable pain-related sodium channel assays and services to accelerate hit-to-lead and lead optimisation programmes
Subscribe to